RxDoctor Payments Data

Mohamad Sayafi

Medical · Carson City, NVNPI 1750053690

Payments from drug & device makers

$702in general payments, 2019–2025

Across 25 payments — averaging $28.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$214
  • Novo Nordisk$160
  • AbbVie$135
  • Biohaven Pharmaceutical Holding Company Ltd.$33
  • Lilly USA, LLC$33
  • Merck$31
  • plus $96 from 5 others

What the payments were for

  • Food & beverage$702100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$702 in reported general payments places this provider in the 45th percentile of 250 medical providers in Nevada.

See all medical providers in Nevada

Medicare billing

Part B allowed, 2024
$52,836
Medicare patients
264
Services billed
841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$22,072
EliquisApixaban21$20,457
Gabapentin30$1,340
Atorvastatin Calcium86$1,300
Losartan Potassium92$1,114
Rosuvastatin Calcium47$900
Levothyroxine Sodium91$892
Tamsulosin Hcl32$829
Celecoxib11$663
Potassium Chloride27$602
Albuterol Sulfate HfaAlbuterol Sulfate28$592
Memantine Hcl13$566
Amlodipine Besylate103$563
Escitalopram Oxalate39$521
Duloxetine Hcl22$502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$160$22,07223 claims
PfizerEliquis$28$20,45721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 250 medical providers in Nevada.

Other medical in Carson City

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →